BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 14699709)

  • 1. Contribution of the type 1 plasminogen activator inhibitor 4G/5G gene polymorphism to impaired fibrinolysis in vital exhaustion.
    von Känel R; Maly FE; Frey K; Fischer JE
    Ital Heart J; 2003 Nov; 4(11):791-6. PubMed ID: 14699709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
    Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
    Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor type 1 serum levels and 4G/5G gene polymorphism in morbidly obese Hispanic patients with non-alcoholic fatty liver disease.
    Espino A; Villagrán A; Vollrath V; Hanckes P; Salas R; Farah A; Solís N; Pizarro M; Escalona A; Boza C; Pérez G; Carrasco G; Padilla O; Miquel JF; Nervi F; Chavez-Tapia NC; Arab JP; Alvarez-Lobos M; Arrese M; Riquelme A
    Ann Hepatol; 2011; 10(4):493-501. PubMed ID: 21911891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome.
    Lin S; Huiya Z; Bo L; Wei W; Yongmei G
    Endocrine; 2009 Dec; 36(3):503-9. PubMed ID: 19856137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
    Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
    Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Plasminogen activator inhibitor-1 (PAI-1) 4G/5G and angiotensin converting enzyme (ACE) I/D gene polymorphisms and fibrinolytic activity in patients with essential hypertension and dyslipidemia].
    Jastrzebska M; Widecka K; Ciechanowicz A; Goracy I; Wesołowska T; Torbus-Lisiecka B; Foltyńska-Nowakowska A; Naruszewicz M
    Pol Arch Med Wewn; 2005 Jan; 113(1):7-20. PubMed ID: 16130596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 4G/5G polymorphism of the plasminogen activator inhibitor gene is associated with the time course of progression to acute coronary syndromes.
    Iwai N; Shimoike H; Nakamura Y; Tamaki S; Kinoshita M
    Atherosclerosis; 1998 Jan; 136(1):109-14. PubMed ID: 9544737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
    Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
    Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of PAI-1 gene promoter-675 (4G/5G) polymorphism on fibrinolytic activity after cardiac surgery employing cardiopulmonary bypass.
    Ozolina A; Strike E; Jaunalksne I; Serova J; Romanova T; Zake LN; Sabelnikovs O; Vanags I
    Medicina (Kaunas); 2012; 48(10):515-20. PubMed ID: 23324247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype.
    Estellés A; Dalmau J; Falcó C; Berbel O; Castelló R; España F; Aznar J
    Thromb Haemost; 2001 Aug; 86(2):647-52. PubMed ID: 11522017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
    Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
    Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter (4G/5G) plasminogen activator inhibitor-1 genotype and plasminogen activator inhibitor-1 levels in blacks, Hispanics, and non-Hispanic whites: the Insulin Resistance Atherosclerosis Study.
    Festa A; D'Agostino R; Rich SS; Jenny NS; Tracy RP; Haffner SM
    Circulation; 2003 May; 107(19):2422-7. PubMed ID: 12719278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4G/5G Polymorphism of the plasminogen activator inhibitor-1 gene is associated with multiple organ dysfunction in critically ill patients.
    Huq MA; Takeyama N; Harada M; Miki Y; Takeuchi A; Inoue S; Nakagawa T; Kanou H; Hirakawa A; Noguchi H
    Acta Haematol; 2012; 127(2):72-80. PubMed ID: 22134139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender-specific association of the plasminogen activator inhibitor-1 4G/5G polymorphism with central arterial blood pressure.
    Björck HM; Eriksson P; Alehagen U; De Basso R; Ljungberg LU; Persson K; Dahlström U; Länne T
    Am J Hypertens; 2011 Jul; 24(7):802-8. PubMed ID: 21490692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels.
    Diamanti-Kandarakis E; Palioniko G; Alexandraki K; Bergiele A; Koutsouba T; Bartzis M
    Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children.
    Berberoğlu M; Evliyaoğlu O; Adiyaman P; Ocal G; Ulukol B; Simşek F; Siklar Z; Törel A; Ozel D; Akar N
    J Pediatr Endocrinol Metab; 2006 May; 19(5):741-8. PubMed ID: 16789641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group.
    Hermans PW; Hibberd ML; Booy R; Daramola O; Hazelzet JA; de Groot R; Levin M
    Lancet; 1999 Aug; 354(9178):556-60. PubMed ID: 10470700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasminogen activator inhibitor 1 4G/5G and -844G/A variants in idiopathic recurrent pregnancy loss.
    Magdoud K; Herbepin VG; Touraine R; Almawi WY; Mahjoub T
    Am J Reprod Immunol; 2013 Sep; 70(3):246-52. PubMed ID: 23521508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global fibrinolytic activity, PAI-1 level, and 4G/5G polymorphism in Thai children with arterial ischemic stroke.
    Natesirinilkul R; Sasanakul W; Chuansumrit A; Kadegasem P; Visudtibhan A; Wongwerawattanakoon P; Sirachainan N
    J Stroke Cerebrovasc Dis; 2014; 23(10):2566-2572. PubMed ID: 25284719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of the 4G/5G polymorphism of PaI-1 gene promoter on PaI-1 levels in obese patients: influence of fat distribution and insulin-resistance.
    Sartori MT; Vettor R; De Pergola G; De Mitrio V; Saggiorato G; Della Mea P; Patrassi GM; Lombardi AM; Fabris R; Girolami A
    Thromb Haemost; 2001 Nov; 86(5):1161-9. PubMed ID: 11816701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.